Comprehensive Add on Study in Japan

PHASE3CompletedINTERVENTIONAL
Enrollment

574

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Linagliptin

Linagliptin once daily

DRUG

Linagliptin

Linagliptin once daily

DRUG

Metformin

Metformin twice or three time per day

DRUG

Metformin

Metformin twice or three time per day

DRUG

Linagliptin

Linagliptin once daily

DRUG

Linagliptin

Linagliptin once daily

DRUG

Linagliptin

Linagliptin once daily

Trial Locations (43)

Unknown

1218.78.008 Boehringer Ingelheim Investigational Site, Akishima, Tokyo

1218.78.030 Boehringer Ingelheim Investigational Site, Amagasaki, Hyogo

1218.78.017 Boehringer Ingelheim Investigational Site, Annaka, Gunma

1218.78.006 Boehringer Ingelheim Investigational Site, Aomori, Aomori

1218.78.007 Boehringer Ingelheim Investigational Site, Aomori, Aomori

1218.78.009 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo

1218.78.013 Boehringer Ingelheim Investigational Site, Chuo-ku, Tokyo

1218.78.032 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka

1218.78.040 Boehringer Ingelheim Investigational Site, Fukuoka, Fukuoka

1218.78.037 Boehringer Ingelheim Investigational Site, Higashi Osaka, Osaka

1218.78.043 Boehringer Ingelheim Investigational Site, Hitachinaka, Ibaraki

1218.78.019 Boehringer Ingelheim Investigational Site, Isesaki, Gunma

1218.78.036 Boehringer Ingelheim Investigational Site, Kashiwara, Osaka

1218.78.026 Boehringer Ingelheim Investigational Site, Kasugai, Aichi

1218.78.038 Boehringer Ingelheim Investigational Site, Kawachinagano, Osaka

1218.78.021 Boehringer Ingelheim Investigational Site, Kitaazumi-gun, Nagano

1218.78.022 Boehringer Ingelheim Investigational Site, Matsumoto, Nagano

1218.78.033 Boehringer Ingelheim Investigational Site, Matsumoto, Nagano

1218.78.012 Boehringer Ingelheim Investigational Site, Meguro-ku, Tokyo

1218.78.041 Boehringer Ingelheim Investigational Site, Meguro-ku, Tokyo

1218.78.034 Boehringer Ingelheim Investigational Site, Morioka, Iwate

1218.78.035 Boehringer Ingelheim Investigational Site, Morioka, Iwate

1218.78.018 Boehringer Ingelheim Investigational Site, Moriya, Ibaraki

1218.78.024 Boehringer Ingelheim Investigational Site, Nagoya, Aichi

1218.78.025 Boehringer Ingelheim Investigational Site, Nagoya, Aichi

1218.78.027 Boehringer Ingelheim Investigational Site, Nagoya, Aichi

1218.78.028 Boehringer Ingelheim Investigational Site, Nagoya, Aichi

1218.78.031 Boehringer Ingelheim Investigational Site, Nagoya, Aichi

1218.78.039 Boehringer Ingelheim Investigational Site, Oita, Oita

1218.78.004 Boehringer Ingelheim Investigational Site, Okinawa, Okinawa

1218.78.016 Boehringer Ingelheim Investigational Site, Sagae, Yamagata

1218.78.001 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1218.78.020 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1218.78.042 Boehringer Ingelheim Investigational Site, Sapporo, Hokkaido

1218.78.005 Boehringer Ingelheim Investigational Site, Shimajiri-gun, Okinawa

1218.78.014 Boehringer Ingelheim Investigational Site, Shinjuku-ku, Tokyo

1218.78.002 Boehringer Ingelheim Investigational Site, Shinjyuku-ku. Tokyo

1218.78.011 Boehringer Ingelheim Investigational Site, Shizuoka, Shizuoka

1218.78.003 Boehringer Ingelheim Investigational Site, Suita, Osaka

1218.78.023 Boehringer Ingelheim Investigational Site, Tokorozawa, Saitama

1218.78.029 Boehringer Ingelheim Investigational Site, Tokorozawa, Saitama

1218.78.010 Boehringer Ingelheim Investigational Site, Tsuchiura, Ibaraki

1218.78.015 Boehringer Ingelheim Investigational Site, Yamagata, Yamagata

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Boehringer Ingelheim

INDUSTRY